Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab and EPOCH in Aggressive T and NK-Cell Lymphomas
NCT00069238Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2003
- Primary completion
- Jun 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in T-cell lymphoma, natural killer cell lymphoma (NKCL), sponsored by National Cancer Institute. Started Sep 2003; status: completed.
02
Drugs
alemtuzumab
03
Conditions
T-cell lymphomanatural killer cell lymphoma (NKCL)
Beyond the preview
Go deeper on NCT00069238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00069238.